News and Educations

A Dear Healthcare Professional letter to physicians about important information concerning safety of the medicinal product MabThera (rituximab) in treatment of patients with rheumatoid arthritis

09.11.2009

Roche d.o.o., in collaboration with the Agency for Medicinal Products and Medical Devices, on 9 November 2009, sent a Dear Healthcare Professional letter to prescribing physicians about MabThera (rituximab) and progressive multifocal leukoencephalopathy (PML) in treatment of patients with rheumatoid arthritis (RA).

more

Dear Healthcare Professional Letter to physicians concerning supply of Cerezyme (imiglucerase) with revised temporary treatment recommendations

27.10.2009

The holder of the marketing authorisations for the medicinal products of Genezyme Corporation in Croatia, the company Medical Intertrade d.o.o., in cooperation with the Agency for Medicinal Products and Medical Devices sent a letter to prescribing physicians in connection with restricted supply of Cerezyme (imiglucerase). The letter contains new, revised temporary treatment recommendations in relation to those published in August 2009.

more

Publication of the new Ordinance on Advertising of Medicinal Products and Homeopathic Medicinal Products

06.10.2009

New Ordinance on Advertising of Medicinal Products and Homeopathic Medicinal Products was published on 30 September 2009 in the Official Gazette of the Republic of Croatia No. 118/09. This Ordinance will come into effect on the eighth day from the date of the publication in the Official Gazette. The link to the Ordinance can be found at the ALMP website, in the Legislation section.

more

Dear Healthcare Professional Letter to physicians concerning supply shortage of Fabrazyme (agalsidase beta) with revised temporary treatment recommendations

29.09.2009

The marketing authorisation holder in the Republic of Croatia for Genezyme Corporation's medicinal products, Medical Intertrade d.o.o., in cooperation with the Agency for Medicinal Products and Medical Devices sent a letter to prescribing physicians concerning supply shortage of Fabrazyme (agalsidase beta). The letter contains the new, revised temporary treatment recommendations compared to those published in July 2009.

more